Slide 1: First Quarter 2016 Earnings Teleconference
First Quarter 2016 Earnings Teleconference May 3, 2016
Slide 2: Introduction
Introduction Chuck Triano Senior Vice President, Investor Relations First Quarter 2016 Earnings
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candid
Slide 4: Opening Remarks
Opening Remarks Ian Read Chairman and Chief Executive Officer First Quarter 2016 Earnings
Slide 5: CEO Perspectives
CEO Perspectives Q1 2016 performance across our Innovative and Established Products businesses was solid Innovative generated 28% operational revenue growth Established generated 24% operational revenue growth (1% excluding legacy Hospira) Our strategy remains unchanged Improving our reven
Slide 6: Financial Review
Financial Review Frank D’Amelio Executive Vice President & Chief Financial Officer First Quarter 2016 Earnings
Slide 7: Income Statement Highlights
Income Statement Highlights ($ Millions, Except Per Share Amounts and Percentages) First Quarter 2016 2015 Change Reported Revenues(1) $13,005 $10,864 20% Adjusted Income(2) 4,155 3,196 30% Adjusted Diluted EPS(2) 0.67 0.51 32% Reported Net Income(1) 3,016 2,376 27% Reported Diluted EPS(1) 0.49 0.38
Slide 8: Impact of Foreign Exchange on Revenues and Select Adjusted Income Components
Impact of Foreign Exchange on Revenues(1) and Select Adjusted Income(1) Components ($ Millions, Except Percentages) Favorable / (Unfavorable) First Quarter 2016 2015 FX Impact Reported Revenues(1) $13,005 $10,864 ($729) (7%) Cost of Sales(1) 2,565 1,807 52 3% SI&A Expenses(1) 3,368 3,078 132 4% R&D
Slide 9: 2016 Financial Guidance
2016 Financial Guidance(1)(2) $51.0 to $53.0 billion Reported Revenues(3) (previously $49.0 to $51.0 billion) Adjusted Cost of Sales(3) as a % of Reported Revenues(3) 21.0% to 22.0% $13.7 to $14.7 billion Adjusted SI&A Expenses(3) (previously $13.2 to $14.2 billion) $7.4 to $7.8 billion Adjusted R&D
Slide 10: Key Takeaways
Key Takeaways Achieved strong Q1 2016 financial performance, with our sixth consecutive quarter of Pfizer standalone operational revenue(1) growth, primarily driven by: Additional selling days in the period as well as strength of Ibrance, Prevnar 13, Eliquis, Xeljanz & Lyrica Raised our 2016 repor
Slide 11: Q&A Session
First Quarter 2016 Earnings Teleconference Q&A Session May 3, 2016
Slide 12: Appendix: Segment Financial Highlights
Appendix Segment Financial Highlights May 3, 2016
Slide 13: Global Innovative Pharmaceutical (GIP) Selected Financial Highlights
Global Innovative Pharmaceutical (GIP) Selected Financial Highlights ($ Millions, Except Percentages) Q1 2016 revenues increased 25% operationally to First Quarter $3,640M vs. Q1 2015 % Change Primarily due to the strong operational performance 2016 2015 Total Oper. of Eliquis globally, Lyrica a
Slide 14: Global Vaccines, Oncology and Consumer Healthcare (VOC) Selected Financial Highlights
Global Vaccines, Oncology and Consumer Healthcare (VOC) Selected Financial Highlights ($ Millions, Except Percentages) First Quarter Q1 2016 revenues increased 33% operationally to $3,394M vs. Q1 2015 % Change 2016 2015 Primarily driven by continued momentum following Total Oper. the U.S. launch
Slide 15: Global Established Pharmaceutical (GEP) Selected Financial Highlights
Global Established Pharmaceutical (GEP) Selected Financial Highlights ($ Millions, Except Percentages) First Quarter Q1 2016 revenues increased 24% operationally to $5,972M vs. Q1 2015 % Change Driven by the inclusion of legacy Hospira operations 2016 2015 Total Oper. (HSP), which contributed $1